Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors Read more about Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors
Xencor Reports First Quarter 2022 Financial Results Read more about Xencor Reports First Quarter 2022 Financial Results
Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022 Read more about Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022
Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022 Read more about Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022 Read more about Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
Xencor Reports Fourth Quarter and Full Year 2021 Financial Results Read more about Xencor Reports Fourth Quarter and Full Year 2021 Financial Results
Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022 Read more about Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022
Xencor to Present at Upcoming Investor Conferences Read more about Xencor to Present at Upcoming Investor Conferences
Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones Read more about Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones
